Skip to main content
Premium Trial:

Request an Annual Quote

To Boost Vaccine Production in Africa

BioNTech plans to set up mRNA vaccine production facilities in Africa, according to the Financial Times. It adds that the move aims to tackle diseases beyond COVID-19.

According to FT, the European Union plans to increase vaccine manufacturing in Africa, which currently must import most vaccines it needs, and BioNTech co-founder Ugur Sahin described his idea to build production facilities there in a video call with European Commission President Ursula von der Leyen ahead of the upcoming G7 meeting.

"From the technology side, there is no reason why [vaccine production in Africa] should not be possible," Sahin tells FT. "And because there's no reason anymore, we have to make it possible."

As Axios has previously reported, mRNA-based vaccines could be applied to a host of diseases, including influenza and malaria, and even cancer. FT notes that BioNTech is developing an mRNA-based vaccine for tuberculosis.

It adds that it will take years for BioNTech to get the facilities up and running. Sahin tells it that he expects it would take about a year to train a partner there to "fill and finish" vaccine does and about four years to ramp up capacity to handle earlier stages of vaccine production.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.